CTLA4 and thyroiditis: However, in contrast, with the endocrine system, the use of anti-CTLA-4 or anti-PD-1 immunotherapy is reported to have a greater potential to cause endocrine issues (such as hypothyroidism, hyperthyroidism, thyroiditis, and adrenal insufficiency) in other cancers [35,36].